view4D pharma plc

4D Pharma’s Blautix “safe and well-tolerated”

The pharmaceutical firm has successfully completed phase I clinical trials for its IBS treatment Blautix

A scientist testing some samples in a lab
Phase I trials typically only assess the safety of a new drug and not its effectiveness

Biotherapeutics firm 4D Pharma PLC (LON:DDDD) Irritable Bowel Syndrome (IBS) treatment, Blautix has passed a phase I clinical trial.

“We have shown Blautix to be safe and well tolerated,” said chief executive Duncan Peyton.

“This trial is providing patient samples that will give the company a better understanding of what is happening in IBS patients undergoing the treatment of Blautix.”

4D is now analysing the samples and data from the trials in greater detail to help develop its understanding of Blautix and to help design the next round of trials.

Phase I trials assess the safety of the drug. The next stage, phase II, is the first test of a new treatment’s efficacy.

Shares rose 19.5p or 2.4% to 850p.

Quick facts: 4D pharma plc

Price: 94.75 GBX

Market: AIM
Market Cap: £62.06 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Stobart Group PLC reports ' strong strategic and operational first-half...

Stobart Group (LON:STOB) CEO Warwick Brady and CFO Lewis Girdwood highlight what they believe to be the 'significant growth potential' within its aviation division and in particular at London Southend airport. Passenger numbers at the airport increased by 41.8% to 1.2 million in the six...

1 day, 7 hours ago

2 min read